^
Association details:
| Biomarker: | HR positive |
|---|---|
| Cancer: | Hormone Receptor Positive Breast Cancer |
| Drug: | Ibrance (palbociclib) (CDK4 inhibitor, CDK6 inhibitor) + Verzenio (abemaciclib) (CDK4 inhibitor, CDK6 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Cyclin-dependent kinase 4/6 inhibitors in combination with fulvestrant for previously treated metastatic hormone receptor-positive breast cancer patients: A systematic review and meta-analysis of randomized clinical trials
Published date:
05/04/2020
Excerpt:
To compare the efficacy and safety profile of the combination of cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors and fulvestrant versus fulvestrant alone in previously treated patients with advanced hormone-receptor positive breast cancer. Use of abemaciclib, palbociclib, or ribociclib in combination with fulvestrant was significantly associated with longer PFS compared to use of fulvestrant alone...
Secondary therapy:
fulvestrant
DOI:
10.1016/j.ctarc.2020.100175
Source:
Title:
A Prospective, Multi-center Real-world Study to Evaluate the Efficacy and Safety of Palbociclib or Abemaciclib in Combination With Endocrine Treatment(ET) in Patients with HR+HER2- Locally Advanced or Metastatic Breast Cancer
Excerpt:
...Pathological examination confirmed HR-positive, HER2-negative breast cancer patients with local recurrence or metastasis evidence. ...
Trial ID:
